Abstract
Immunotherapy, which stimulates the anti-tumor immune response, has significantly modified the prognosis of advanced stage melanoma. Anti-CTLA4 monoclonal antibody, ipilimumab, showed a benefit on survival compared to chemotherapy in 2011. Anti-PD1, nivolumab and pembrolizumab subsequently showed superior clinical benefit including overall survival and tolerance over anti-CTLA4. Currently, the combination of ipilimumab and nivolumab appears as the most effective immunotherapy but the toxicity of this regimen is a limitation. Anti-PD1 antibodies have also been evaluated in the adjuvant setting for patients with stage III or IV resected melanoma where they have shown a significant benefit in term of relapse-free-survival. Studies are underway to evaluate these drugs in stage II resected melanoma and in neo-adjuvant setting with promising results.
| Translated title of the contribution | IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF ADVANCED STAGE MELANOMA |
|---|---|
| Original language | French |
| Pages (from-to) | 471-474 |
| Number of pages | 4 |
| Journal | Revue du Praticien |
| Volume | 70 |
| Issue number | 5 |
| Publication status | Published - 1 May 2020 |